

**REMARKS**

Claims 1, 23-36 and 49 are pending in the subject application. In response to the rejections in the *Final Office Action*, and solely to expedite prosecution of the present case, claims 1, 29 and 49 have been amended to recite that the constituent A may be “a monomer of TKPPR, or a monomer of a TKPPR analogue which contains TKPPR and which specifically binds to NP-1 or cells that express NP-1 with avidity that is equal to or greater than TKPPR.”

No new matter has been added. Applicants hereby respectfully reserve the right to pursue claims of broader scope in subsequent continuation or divisional applications.

**Rejections Under 35 U.S.C. § 112, ¶ 1**

Claims 1, 23-32, 34-36 and 49 stand rejected under 35 U.S.C. § 112, ¶ 1 as purportedly not being enabling for “any analogue of TKPPR . . . as monomer A.” (*Final Office Action*, p. 2).

Applicants have previously argued, for reasons of record, that such rejection should be withdrawn. However, without acquiescing to the merits of the rejection and solely to expedite allowance of the present claims, Applicants have herein amended claims 1, 29 and 49 to recite that the constituent A may be “a monomer of TKPPR, or a monomer of a TKPPR analogue which contains TKPPR and which specifically binds to NP-1 or cells that express NP-1 with avidity that is equal to or greater than TKPPR.”

The *Final Office Action* acknowledged that the Specification “[is] enabling for the peptide TKPPR or an analogue which contains therein ‘TKPPR’. . . which specifically binds to NP-1 or cells that express NP-1 with avidity that is equal to or greater than TKPPR as monomer A . . . .” Therefore, Applicants respectfully submit that the rejection of claims 1, 23-32, 34-36

and 49 under 35 U.S.C. § 112 ¶ 1 has been overcome, and request that it be withdrawn and a Notice of Allowance issued in the present case.

### CONCLUSION

In view of the preceding remarks, Applicants maintain that the claims are now in condition for allowance, early notice of which is earnestly sought.

No fee(s), other than the fee for extension of time, are believed to be due in connection with the filing of this *After Final Amendment*. The Director is hereby authorized to charge any additional fees due or credit any overpayment to Deposit Account No. 50-0540.

If there are any outstanding issues the Examiner is respectfully invited to contact Applicants' undersigned attorneys to resolve them.

Respectfully submitted,

Dated: January 18, 2006

By:

Rachel J. Lin Reg. No. 51,098

Donald L. Rhoads, Reg. No. 34,705

Rachel J. Lin, Reg. No. 51,098

KRAMER LEVIN NAFTALIS & FRANKEL LLP

1177 Avenue of the Americas

New York, New York 10036

(212) 715-9100 (telephone)

(212) 715-8000 (facsimile)